Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0CLZRU
ADC Name	Alpha-CD22-LC-V205C-10
Synonyms	AlphaCD22-LC-V205C-10 Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Diffuse large B-cell lymphoma [ICD11:2A81] Investigative
Drug-to-Antibody Ratio	2
	3D MOL	2D MOL
Antibody Name	Anti-CD22-LC-V205C		Antibody Info
Antigen Name	B-cell receptor CD22 (CD22)		Antigen Info
Payload Name	seco-CBI-dimer		Payload Info
Therapeutic Target	Human Deoxyribonucleic acid (hDNA)		Target Info
Linker Name	Mc-peptidomimetic based linker 10		Linker Info

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	0.01	nM	WSU-DLCL2 cells	Diffuse large B-cell lymphoma
Half Maximal Inhibitory Concentration (IC50)	0.04	nM	BJAB cells	Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50)	92	nM	Jurkat cells	T acute lymphoblastic leukemia

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive CD22 expression (CD22+++/++)
Method Description	Seco-CBI-Dimer TDCs Exhibit Potent Antigen-Dependent Antiproliferation Effects in Vitro. All cell-based assay results are reported as the arithmetic mean of at least three separate runs (n = 3).
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Positive CD22 expression (CD22+++/++)
Method Description	Seco-CBI-Dimer TDCs Exhibit Potent Antigen-Dependent Antiproliferation Effects in Vitro. All cell-based assay results are reported as the arithmetic mean of at least three separate runs (n = 3).
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	92.00 nM	Positive CD22 expression (CD22+++/++)
Method Description	Seco-CBI-Dimer TDCs Exhibit Potent Antigen-Dependent Antiproliferation Effects in Vitro. All cell-based assay results are reported as the arithmetic mean of at least three separate runs (n = 3).
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

References

Ref 1	Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. Bioconjug Chem. 2019 May 15;30(5):1356-1370. doi: 10.1021/acs.bioconjchem.9b00133. Epub 2019 Apr 22.